(Q47385994)

English

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats

scientific article published on 17 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

1 reference

based on heuristic

inferred from title

author name string

Matthew R Hayes

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

Scott E Kanoski

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

Amber L Alhadeff

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

Harvey J Grill

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

publication date

17 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

19

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

7

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

1342-1349

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Role of the glucagon-like-peptide-1 receptor in the control of energy balance

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Exenatide and weight loss.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Liraglutide for weight loss in obese people

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian h

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Exenatide therapy in insulin-treated type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Hyperleptinemia is required for the development of leptin resistance

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

21 January 2018

Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokinin

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

31 March 2020

Adaptation to a high-fat diet leads to hyperphagia and diminished sensitivity to cholecystokinin in rats.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

31 March 2020

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2011.50

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/OBY.2011.50

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/21415845

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47385994&oldid=2154620748"